Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials

Crown Bioscience a global contract research organization CRO and JSR Life Sciences company has announced that its collaborative work with HanX Biopharmaceutical Co. Ltd. HanX employing a unique and broad portfolio of preclinical modeling in support of HanXs successful FDA Investigational New Drug IND application has been published in Scientific Reports a journal within the Nature portfolio.

Related Keywords

United States ,San Diego ,California ,Australia ,China ,Ludovic Bourre ,Crown Bioscience ,Henry Li ,Hubrecht Organoid Technology ,Hanx Biopharmaceutical Co Ltd ,Life Sciences ,New Drug ,Scientific Reports ,Rajib Lymphoma ,Chief Executive Officer ,Chief Scientific Officer ,Tuesday August ,Hubrecht Organoid ,Media Contact ,Crown Bioscience Hanx Biopharmaceutical Hx009 Clinical Trials Contract Research Organization Jsr Life Sciences Investigational New Drug Scientific Reports Monoclonal Antibody Antilymphoma Activity Patientderived Xenograft Pdx Cd47 Blymphoma Hugemm Lymphoma Treatment Of Henry Li Partnership Ludovic Bourre Hanxs Therapeutics Scientists Immunooncology Collaborations ,